Related Experiment Video
Updated: Feb 21, 2026
Investigating Intestinal Inflammation in DSS-induced Model of IBD
Published on: February 1, 2012
D-Dimer levels are correlated with disease activity in Crohn's patients
Junwu Zhang1, Zhen Guo2, Wei Yang3
1Department of Clinical Laboratory, Wenzhou Traditional Chinese Medicine Hospital, 325000 Wenzhou, China.
Insights
The Crohn's Disease Activity Index (CDAI) shows a positive correlation with D-Dimer levels in Crohn's disease patients. This suggests D-Dimer may serve as a novel biomarker for assessing disease activity.
Area of Science:
- Gastroenterology
- Hematology
- Biomarker Discovery
Background:
- Assessing Crohn's disease (CD) activity is crucial for patient management.
- The relationship between the Crohn's Disease Activity Index (CDAI) and coagulation function requires further clarification.
Purpose of the Study:
- To investigate the association between CDAI and various coagulation and fibrinolysis parameters.
- To determine if D-Dimer levels can serve as a marker for CD activity.
Main Methods:
- Retrospective observational cohort study of 108 CD patients from two centers.
- Calculated CDAI and measured prothrombin time (PT), activated partial thromboplastin time (APTT), thrombin time (TT), international normalization ratio (INR), fibrinogen (Fg), and plasma D-Dimer.
- Compared parameters between healthy controls and CD patients, and between high and low CDAI groups.
Main Results:
- Significant differences in PT, APTT, TT, INR, Fg, and D-Dimer were observed between CD patients and healthy controls.
- No significant differences were found between high and low CDAI groups for these parameters.
- CDAI positively correlated with D-Dimer levels in CD patients across both hospitals (r=0.3268, p=0.0042; r=0.5553, p=0.0008).
Conclusions:
- D-Dimer levels are significantly correlated with CDAI in CD patients.
- Plasma D-Dimer shows potential as a novel biomarker for assessing CD disease activity.
Abstract:
Various indices have been used to assess Crohn's disease (CD). However, the question of whether the Crohn's Disease Activity Index (CDAI) is associated with coagulation function has not been fully confirmed. In this study, we examined the association between CDAI and the coagulation and fibrinolysis parameters. In a retrospective and observational cohort study, the CDAI of 108 patients from two hospital centers was calculated, and its correlations with the prothrombin time (PT), activated partial thromboplastin time (APTT), thrombin time (TT), international normalization ratio (INR), fibrinogen (Fg) and plasma D-Dimer were investigated. Significant differences were found for PT, APTT, TT, INR, Fg and D-Dimer between the healthy controls and CD patients. However, no significant difference was found between the CDAI-High and CDAI-Low groups of CD patients. Moreover, the CDAI was positively correlated with the level of D-Dimer in CD patients of two hospitals, regardless of the detection method (hospital 1: r=0.3268, p= 0.0042; hospital 2: r=0.5553, p=0.0008). Among the blood coagulation and fibrinolysis parameters, the D-Dimer level was highly correlated with CDAI in CD patients. Thus, the level of D-Dimer expression may be a promising new marker for assessing CD disease activity.
More Related Videos
09:44Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis
Published on: October 14, 2025
09:11Systematic Scoring Analysis for Intestinal Inflammation in a Murine Dextran Sodium Sulfate-Induced Colitis Model
Published on: February 14, 2021
Related Concept Videos
01:30Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
01:22Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids